Jianwei Du

Dr. Jianwei Du


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
WBWenzhen Bu
Wenzhen Bu
YSYu Shi
Yu Shi
XHXueping Huang
Xueping Huang
SWShang Wu
Shang Wu
LJLetao Jiang
Letao Jiang
JDJianwei Du
Jianwei Du
The senescence of nucleus pulposus (NP) cells (NPCs), which is induced by the anomalous accumulation of reactive oxygen species (ROS), is a major cause of intervertebral disc degeneration (IVDD). In this research, glutathione-doped carbon dots (GSH-CDs), which are novel carbon dot antioxidant nanozymes, were successfully constructed to remove large amounts of ROS for the maintenance of NP tissue at the physical redox level. After significantly scavenging endogenous ROS via exerting antioxidant activities, such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and total antioxidant capacity, GSH-CDs with good biocompatibility have been demonstrated to effectively improve mitochondrial dysfunction and rescue NPCs from senescence, catabolism, and inflammatory factors in vivo and in vitro. In vivo imaging data and histomorphological indicators, such as the disc height index (DHI) and Pfirrmann grade, demonstrated prominent improvements in the progression of IVDD after the topical application of GSH-CDs. In summary, this study investigated the GSH-CDs nanozyme, which possesses excellent potential to inhibit the senescence of NPCs with mitochondrial lesions induced by the excessive accumulation of ROS and improve the progression of IVDD, providing potential therapeutic options for clinical treatment. Graphical Abstract

13 September 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
CQChen Qian
Chen Qian
DWDeluo Wu
Deluo Wu
JDJianwei Du
Jianwei Du
Sarcomas is a complex group of malignant diseasse with undetermined molecular mechanisms. Receptor interacting serine/threonine kinase 3 (RIPK3) is a necroptosis‑ and apoptosis‑related marker that has been implicated in several immune‑associated diseases and aggressive malignant tumours. In the present study, publicly available transcriptome sequencing data were collected from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research To Generate Effective Treatments (TARGET) databases and extensive data mining was performed, focusing on RIPK3 and its potential function in the modulation of gene expression and signaling pathways, immune checkpoints and cell infiltration. Analysis of TCGA and TARGET data revealed 603 up‑ and 260 downregulated genes in the higher RIPK3 expression group compared with the lower RIPK3 expression groups, with transmembrane channel like 8 and transmembrane protein 97 as the top up‑ and downregulated genes, respectively. Further pathway analysis revealed that the overexpressed genes were enriched in ‘cytokine‑cytokine receptor interaction’. Higher RIPK3 was found to be associated with improved survival, the immune checkpoint gene hepatitis A virus cellular receptor 2 (HAVCR2) and an improved response to immune blockade therapy. The potential modulation of HAVCR2 expression by RIPK3 was confirmed by reverse transcription‑quantiative PCR in KHOS and 143B human osteosarcoma cell lines. Immune cell infiltration analysis revealed that RIPK3 was positively associated with macrophage and monocyte infiltration, suggesting that RIPK3 executes its function through these immune cells. These findings led to the hypothesis that increased RIPK3 expression may result in improved survival, possibly by regulating the immune checkpoint HAVCR2. In conclusion, the present study comprehensively elucidated the RIPK3 profile with regard to sarcoma survival, transcriptome expression, immune checkpoint therapy and immune cell infiltration. These findings suggest that RIPK3 is potentially a therapeutic target for sarcoma.

16 February 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
XWXinglong Wang
Xinglong Wang
GLGongke Li
Gongke Li
KLKe Li
Ke Li
YSYu Shi
Yu Shi
WLWenzheng Lin
Wenzheng Lin
HWHuihui Wang
Huihui Wang
Targeted delivery of antitumor drugs has been recognized as a promising therapeutic modality to improve treatment efficacy, reduce the toxic side effects and inhibit tumor recurrence. In this study, based on the high biocompatibility, large specific surface area, and easy surface modification of small-sized hollow mesoporous silica nanoparticles β-cyclodextrin (β-CD)-benzimidazole (BM) supramolecular nanovalve, together with bone-targeted alendronate sodium (ALN) were constructed on the surface of small-sized HMSNs. The drug loading capacity and efficiency of apatinib (Apa) in HMSNs/BM-Apa-CD-PEG-ALN (HACA) were 65% and 25%, respectively. More importantly, HACA nanoparticles can release the antitumor drug Apa efficiently compared with non-targeted HMSNs nanoparticles in the acidic microenvironment of the tumor. In vitro studies showed that HACA nanoparticles exhibited the most potent cytotoxicity in osteosarcoma cells (143B cells) and significantly reduced cell proliferation, migration and invasion. Therefore, the drug-efficient release of antitumor effect of HACA nanoparticles is a promising way to treat osteosarcoma.

8 August 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
SWShang Wu
Shang Wu
WBWenzhen Bu
Wenzhen Bu
DWDeluo Wu
Deluo Wu
JDJianwei Du
Jianwei Du

25 September 2026 in Journal of Fluorescence
Verified
Journal Article
Closed access
PDF file
LJLetao Jiang
Letao Jiang
KFKai Feng
Kai Feng
YZYu Zhang
Yu Zhang
YZYi Zhou
Yi Zhou
SWShang Wu
Shang Wu
JWJing Wang
Jing Wang